Tector Lecture: Changes in Diabetes Management in Our Lifetime and Future Areas (Epigenetic/ In Utero, etc.)
Nov 25, 2015

Dr. Tina Kader

Assistant Professor, Department of Medicine, McGill University


Tector Lecture: Changes in Diabetes Management in Our Lifetime and Future Areas (Epigenetic/ In Utero, etc.)


Diabetes has evolved immensely in past 20 years. Type 2 diabetes 20 years ago only had two classes of medications. We now have 7 classes and each one affecting the different pathophysiology of diabetes. names like ddp4 inhibitors; slglt2 inhibitors;glp 1 agonist are now common medications to treat diabetes. We are evolving to meds that get to goal without the hypoglycemia and weight gain of the older medications. Insulin therapy for both type 1 and type 2 diabetes has changed equally;. going from 2 insulins now to may different types of insulins which improve diabetes control and more recently the pump is becoming more common for insulin treated patients. Technology is moving at a fast pace with new sensors;newer patchpumps; and linking of sensor reading to pump activity. unfortunately diabetes is still on the rise along with obesity epidemic. some theoires include epigenetics and having gestational diabebetes in pregnancy may be producing permanent changes in fetus ; putting the next generation at earlier rates of diabetes and obesity.

  1. Understanding the changing role of oral agents in treatment of diabetes.
  2. Understand the newer insulins in treating type 2 and type 1 diabetes.
  3. Update knowledge of newer technology including pumps and sensors and where they fit in.
  4. Understand the epigenetics of diabetes and what can we do to prevent this



Endocrinology/Endocrinologie; Diabetes/Diab├Ętes; Dept. of Family Med. CPD - The Annual Refresher Course;

You must login to view this conference
ACCESS As Returning User



Copyright © 2002-2018 Continuing Professional Development (CPD) Office,
Faculty of Medicine, McGill University